FDA ap­proves Ver­ri­ca's skin in­fec­tion treat­ment, en­ters in­to non-bind­ing term sheet for $125M loan

Ver­ri­ca Phar­ma­ceu­ti­cals’ drug-de­vice com­bi­na­tion prod­uct is now the first FDA-ap­proved treat­ment for mol­lus­cum con­ta­gio­sum, a com­mon skin in­fec­tion.

On Fri­day the FDA ap­proved Ycanth, a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER